ArticleFrontiers in cardiovascular medicine2025
A risk prediction nomogram for in-stent restenosis in patients with coronary heart disease: first exploratory analysis based on the substrate materials of drug-eluting stents.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined Prognostic Value of Triglyceride-Glucose Index and Bilirubin in Drug-Eluting Stent Restenosis: From Clinical Risk Stratification to Exploratory Vascular-Cell Findings.Cardiovascular drugs and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to develop and validate a predictive nomogram for identifying the risk factors of in-stent restenosis (ISR). In addition, for the first time, we quantified the clinical effect of the substrate materials of DES. Methods: We retrospectively enrolled 402 patients with coronary heart disease (CHD) who underwent initial percutaneous coronary intervention (PCI) at the Affiliated Hospital of Qingdao University between January 1, 2012, and June 1, 2022. LASSO regression and logistic regression analyses were conducted to identify the independent risk factors of ISR. A predictive nomogram was subsequently developed. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), clinical impact curve (CIC), and calibration curves. Furthermore, nested modeling was conducted to evaluate the incremental predictive value of the substrate materials of DES. Results: BMI, SBP, LVDD, number of target vessels, mean diameter of stent and substrate materials of DES were identified as independent predictors of ISR. A predictive nomogram model was successfully developed, exhibiting good performance in the training set (AUC = 0.734, 95% CI: 0.676-0.792; Brier score = 0.193, 95% CI: 0.173-0.213; calibration slope = 1.000, 95% CI: 0.706-1.359; Hosmer-Lemeshow Conclusions: BMI, SBP, LVDD, number of target vessels, mean diameter of stent, and substrate materials of DES are independent predictors of ISR. The nomogram model exhibited good predictive value for ISR. This is the first study demonstrating the significance of substrate material selection for assessing the risk of ISR in patients. Future validation through prospective studies or larger sample sizes is still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.